FRACTION: protocol of a phase II study of Fedratinib and Nivolumab combination in patients with myelofibrosis and resistance or suboptimal response to JAK-inhibitor treatment of the German MPN study group (GSG-MPN).
- DOI
- 10.1007/s00277-024-05867-w
- Published
- 2024 Aug
- Container
- Annals of hematology
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1007/s00277-024-05867-w,
title = {FRACTION: protocol of a phase II study of Fedratinib and Nivolumab combination in patients with myelofibrosis and resistance or suboptimal response to JAK-inhibitor treatment of the German MPN study group (GSG-MPN).},
author = {Isfort S and von Bubnoff N and Al-Ali HK and Becker H and Götze T and le Coutre P and Griesshammer M and Moskwa C and Wohn L and Riedel J and Palandri F and Manz K and Hochhaus A and Döhner K and Heidel FH},
year = {2024},
journal = {Annals of hematology},
doi = {10.1007/s00277-024-05867-w},
url = {https://doi.org/10.1007/s00277-024-05867-w}
}RIS
TY - JOUR TI - FRACTION: protocol of a phase II study of Fedratinib and Nivolumab combination in patients with myelofibrosis and resistance or suboptimal response to JAK-inhibitor treatment of the German MPN study group (GSG-MPN). AU - Isfort S AU - von Bubnoff N AU - Al-Ali HK AU - Becker H AU - Götze T AU - le Coutre P AU - Griesshammer M AU - Moskwa C AU - Wohn L AU - Riedel J AU - Palandri F AU - Manz K AU - Hochhaus A AU - Döhner K AU - Heidel FH PY - 2024 JO - Annals of hematology DO - 10.1007/s00277-024-05867-w UR - https://doi.org/10.1007/s00277-024-05867-w ER -
APA
S, I., N, V. B., HK, A., H, B., T, G., P, L. C., M, G., C, M., L, W., J, R., F, P., K, M., A, H., K, D., & FH, H. (2024). FRACTION: protocol of a phase II study of Fedratinib and Nivolumab combination in patients with myelofibrosis and resistance or suboptimal response to JAK-inhibitor treatment of the German MPN study group (GSG-MPN).. Annals of hematology. https://doi.org/10.1007/s00277-024-05867-w
Source records
- pubmed · retrieved 2026-09-25T19:54:43.048Z
- europe-pmc · retrieved 2026-09-25T19:54:43.064Z